Impact of platelet-lymphocyte ratio after robot-assisted partial nephrectomy with renorrhaphy
- PMID: 39730921
- PMCID: PMC11680792
- DOI: 10.1038/s41598-024-82197-x
Impact of platelet-lymphocyte ratio after robot-assisted partial nephrectomy with renorrhaphy
Abstract
Renorrhaphy is often performed after tumor resection during robotic-assisted laparoscopic partial nephrectomy (RAPN). This study aimed to investigate the association between renorrhaphy performance and inflammatory markers. A retrospective cohort study was conducted including patients with renal cell carcinoma who underwent RAPN at eight institutions in Japan between April 2016 and November 2023. The primary endpoint was the association between the renorrhaphy performance in RAPN and the postoperative inflammatory markers. The secondary endpoints were perioperative outcomes in patients with and without renorrhaphy. The patients were divided into two groups at the time of RAPN: those who underwent renorrhaphy (renorrhaphy group) and those who did not (omitted group). In total, 934 patients were enrolled in this study. After propensity score matching, the rate of change in C-reactive protein and neutrophil-lymphocyte ratio on postoperative day 28 were not significant difference between the two groups. In contrast, the rate of change in platelet-lymphocyte ratio (PLR) on postoperative day 28 was significantly higher in renorrhaphy group than omitted group. Regarding surgical outcomes, the renorrhaphy group had a significantly longer hospital stay, operative time, and warm ischemia time (P = 0.038, P = 0.022, and P = 0.009, respectively) than the omitted group did. Furthermore, the omitted group had a significantly higher rate of Trifecta achievement than the renorrhaphy group did. This study demonstrated that renorrhaphy performance in RAPN was significantly associated with the higher value of postoperative PLR.
Keywords: Platelet-to-lymphocyte ratio; Renal cell carcinoma; Renorrhaphy; Robot-assisted partial nephrectomy.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Mie University (January 4, 2023 / H2022-114). Consent to participate: Owing to the retrospective observational nature of this study, the need for informed consent was waived. Consent for publication: Patient consents were not applicable for this retrospective study.
Similar articles
-
Comparison of perioperative outcomes of robot-assisted partial nephrectomy without renorrhaphy: Comparative outcomes of cT1a versus cT1b renal tumors.Int J Urol. 2019 Sep;26(9):885-889. doi: 10.1111/iju.14046. Epub 2019 Jun 30. Int J Urol. 2019. PMID: 31257682
-
The Impact of Postoperative Renal Function Recovery after Laparoscopic and Robot-Assisted Partial Nephrectomy in Patients with Renal Cell Carcinoma.Medicina (Kaunas). 2022 Mar 27;58(4):485. doi: 10.3390/medicina58040485. Medicina (Kaunas). 2022. PMID: 35454324 Free PMC article.
-
Comparison of surgical outcomes of robot-assisted laparoscopic partial nephrectomy performed by a single experienced surgeon according to two reconstruction methods, including single-layer and double-layer renorrhaphy.J Robot Surg. 2024 Jul 27;18(1):296. doi: 10.1007/s11701-024-02050-1. J Robot Surg. 2024. PMID: 39068347
-
Comparison of the perioperative outcomes of robot-assisted laparoscopic transperitoneal versus retraperitoneal partial nephrectomy for posterior-lateral renal tumors: a systematic review and meta-analysis.J Robot Surg. 2024 Apr 29;18(1):186. doi: 10.1007/s11701-024-01963-1. J Robot Surg. 2024. PMID: 38683492
-
Expanding utilization of robotic partial nephrectomy for clinical T1b and complex T1a renal masses.World J Urol. 2013 Jun;31(3):499-504. doi: 10.1007/s00345-013-1095-2. Epub 2013 May 5. World J Urol. 2013. PMID: 23645411 Review.
References
-
- Sasaki, T. et al. Urological cancer statistics on incidence from 1975 to 2019 and mortality from 1958 to 2022 in Japan. Int. J. Clin. Oncol.29, 1088–1095 (2024). - PubMed
-
- Ljungberg, B. et al. European association of urology guidelines on renal cell carcinoma: the 2022 update. Eur. Urol.82, 399–410 (2022). - PubMed
-
- Campbell, S. C. et al. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I. J. Urol.206, 199–208 (2021). - PubMed
-
- Porpiglia, F. et al. Partial nephrectomy in clinical T1b renal tumors: multicenter comparative study of open, laparoscopic and robot-assisted approach (the RECORd Project). Urology89, 45–53 (2016). - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous